Singapore Institute of Advanced Medicine (SGX:9G2) loss after tax and total comprehensive loss from continuing operations for the six moths ended June 30 widened 67% year over year to SG$16.2 million from SG$9.7 million, a filing with the Singapore Exchange said on Tuesday.
Revenue remained relatively unchanged at SG$8.1 million for the period despite increase in revenue from radiation therapy and medical oncology services.
Shares of the medical services company plunged nearly 15% in recent trading.
Price (SGD): S$67.60, Change: S$+0.39, Percent Change: +0.58%
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。